Viewpoint Molecular Targeting, Inc.

Viewpoint Molecular Targeting, Inc. is a pioneering radiopharmaceutical company that focuses on developing precision oncology therapeutics and complementary diagnostic imaging agents, with its slogan being "Targeted α-Particle Radiotherapy for Cancer." The company's leading 𝛼-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Additionally, Viewpoint is also engaged in the development of complementary diagnostics that utilize the same targeting peptide, offering the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. The company's melanoma (VMT01) and neuroendocrine tumor (VMT-𝛼-NET) programs are entering Phase 1 imaging studies, followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions. Founded in 2008 and headquartered in the United States, Viewpoint Molecular Targeting received its latest investment of $5.00M in the form of a grant from the National Cancer Institute on 21 January 2021. The company operates within the Biotechnology, Health Care, and Pharmaceutical industries.